Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Wegovy · Ozempic · Rybelsus
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: GLP-1 analogue peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
GLP-1 receptor agonism affects appetite, insulin/glucagon physiology and gastric emptying.
Evidence and critical reading
Reported scientific and empirical uses
Reported glycemic control · Cardiovascular and vascular function · Reported weight management
Clinical use in defined products and commercial vial use for weight control require formulation/indication identification.
Human evidence
STEP-1 demonstrated weight reduction in adults with overweight/obesity; evidence is product-, population- and indication-specific.
Preclinical evidence
Preclinical receptor work supports mechanism; clinical outcomes should take priority.
Critical reading and limitations
STEP-1 provides comparative weight-loss evidence in a defined population; it does not validate alternative salts or unidentified supplier material.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Once-Weekly Semaglutide in Adults with Overweight or Obesity.
2.4 mg · Target maintenance amount; not a starting amount
- Frequency
- Weekly
- Duration
- 68 weeks
- Route
- Subcutaneous
- Context
- STEP-1: adults with overweight/obesity without diabetes; target, not starting dose.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID33567185 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
US/EU: authorized medicines with distinct indications and presentations; check each current label. No approval is transferred to research-market preparations.
Adverse effects and unknowns
GI effects, pancreatitis/gallbladder warnings and dehydration-related renal injury. US contraindications include MTC/MEN2 and serious hypersensitivity. Insulin/secretagogues increase hypoglycemia risk; oral drug absorption may be affected.
GI symptoms and label risks apply; combinations with other agonists need independent assessment.
Contraindications
US Wegovy: personal/family medullary thyroid carcinoma or MEN2 and serious hypersensitivity; confirm formulation/indication.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Insulin/secretagogues increase hypoglycemia risk; delayed gastric emptying may affect oral-drug absorption.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID33567185 · Randomized controlled trial
Adults without diabetes with overweight/obesity.
Weekly SC, 68 weeks.
Mean weight change −14.9% versus −2.4% with placebo.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 1961
PMID40544433 · Randomized controlled trial
Adults without diabetes; four groups.
Weekly SC, 68 weeks.
CagriSema −20.4% versus −3.0% with placebo; individual arms included.
An exact-combination trial does not validate other cagrilintide stacks, supplier blends or the same synergy.
n = 3417
Trials attributed in the package
NCT03548935 · STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityRegistry status: CompletedLast update posted: November 19, 2021Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Semaglutide · 785 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07878494 · Dietary, Medication, and Endoscopic Interventions for Post-Bariatric HypoglycemiaRegistry status: Not yet recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT06715514 · Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose HomeostasisRegistry status: Active, not recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07677865 · GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationRegistry status: WithdrawnLast update posted: October 16, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- EMA-WEG
October 16, 2026
- PMID33567185
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group.
October 16, 2026
- PMID40544433
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group.
October 16, 2026
- R30
- REG-WEG
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026